[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Competitor Analysis: hTERT-Targeted Immunotherapy

June 2018 | 20 pages | ID: CFB8811AAEBEN
La Merie Publishing

US$ 177.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Competitor Analysis: hTERT-Targeted Immunotherapy

This Competitive Intelligence report analyzes the competitive field of hTERT-Targeted Immunotherapies as of June 2018 in a tabulated format with structured listings of industry-relevant data.

Human telomerase reverse transcriptase (hTERT), a catalytic subunit of telomerase, is one of two essential components of telomerase, an enzyme complex that generates and maintains telomeres. Telomerase is expressed mainly in embryonic and adult stem cells. Telomere biology has recently been implicated in the pathogenesis of a variety of diseases, and mutations in telomerase components result in a predisposition to solid malignancies. More recent findings show that TERT is not only expressed in late stage primary tumor cells and metastatic cells, but also expressed in incipient cancer stem cells and/or tumor-initiating cells, indicating that TERT has essential roles at every stage of tumorigenesis.

The intracellular protein hTERT is widely overexpressed in human cancers including prostate cancer. Along with its regulation of the telomere, hTERT was also shown to regulate various signal transduction mechanisms involving DNA damage response, cell cycle checkpoint, and apoptosis. The majority of human solid tumors display telomerase activity, which was found to be well correlated with hTERT expression, and hTERT inhibition led to reduced telomerase activity and telomere length.

The report includes a compilation of currently active projects in research and development of vaccines, Cytotoxic T-Lymphocytes (CTLs), small molecules and oncolytic viruses targeting human telomerase reverse transcriptase (hTERT). In addition, the report lists company- and institution-specific R&D pipelines of hTERT-Targeted Immunotherapies. Competitor projects are listed in a tabular format providing information on:
  • Drug Codes,
  • Target/Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

hTERT-Selective Cancer Vaccines
hTERT-Specific, Multi-Target Cancer Vaccines
hTERT-Targeted Adoptive Cell Therapy
Other hTERT-Targeted Immunotherapies


More Publications